Health and Healthcare
5864 Articles
NewLink Genetics shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with…
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain…
Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to…
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for…
Intra-Cellular Therapy shares practically doubled on Monday after the firm announced that the FDA has approved Caplyta for the treatment…
NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval…
Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with…
This Wedbush analyst sees close to 200% in potential upside in Paratek Pharmaceuticals beyond the massive one-day gain on Thursday.
The U.S. Department of Health and Human Services has awarded Paratek Pharmaceuticals a pact to support development of its treatment…
When most investors and consumers think of antitrust issues and monopolies, they probably think of big giant multinational companies with…
Syros Pharma and Global Blood Therapeutics shares were on the move on Wednesday after the companies announced a collaboration to…
Solid Biosciences shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy.
Adamas Pharma shares dropped sharply on Tuesday after the firm reported results from its late-stage multiple sclerosis study.
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support…
Proteostasis shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis study. What comes…
Our top personal finance-related articles today. Your wallet will thank you later.